Dose Optimization Trial of CD19 Redirected Autologous T Cells

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2013
This is a randomized, open-label, parallel group study to determine the optimal dose of CART-19 cells (autologous T cells expressing CD19 chimeric antigen receptors expressing tandem TCR Zeta and 4-1 BB co-stimulatory domains) of the two dose levels being assessed (1-5x10e8 vs. 1-5x10e7 CART-19 cells). This trial will be conducted in two stages.
Epistemonikos ID: 5d00166c408d742670ba2e92a578c20794df9629
First added on: May 11, 2024